Xiaoyu Zhu
- Oncology top 2%
- HER2/EGFR in Cancer Research 19
- Cancer Treatment and Pharmacology 15
- Polyomavirus and related diseases 10
- Genetics top 5%
- Hematology top 5%
- Hematopoietic Stem Cell Transplantation 43
- Acute Myeloid Leukemia Research 17
-
- Advanced Breast Cancer Therapies 20
- Cancer Research top 10%
-
- Immune Cell Function and Interaction 22
-
- Cytomegalovirus and herpesvirus research 12
- Cited by
- OncologyGeneticsHematology
- Partner nations
- ChinaUnited StatesCanada
In The Last Decade
Xiaoyu Zhu
113 papers receiving 2.2k citations
Peers
Comparison fields: 5 of 122
- Oncology 1.0k
- Genetics 346
- Hematology 255
- Pulmonary and Respiratory Medicine 739
- Cancer Research 281
Countries citing papers authored by Xiaoyu Zhu
This map shows the geographic impact of Xiaoyu Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoyu Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoyu Zhu more than expected).
Fields of papers citing papers by Xiaoyu Zhu
This network shows the impact of papers produced by Xiaoyu Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoyu Zhu. The network helps show where Xiaoyu Zhu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Xiaoyu Zhu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 2 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 2 | |
| 6 | 2024 | 6 | |
| 7 | 2024 | 0 | |
| 8 | 2023 | 2 | |
| 9 | 2023 | 9 | |
| 10 | 2023 | 39 | |
| 11 | 2022 | 13 | |
| 12 | 2020 | 25 | |
| 13 | 2020 | 14 | |
| 14 | 2019 | 61 | |
| 15 | 2019 | 247 | |
| 16 | 2013 | 35 | |
| 17 | 2012 | 1 | |
| 18 | The protective effect of Shenqi Fuzheng Injection on immune function of BALB/ c mice after chemo--therapy | 2006 | 1 |
| 19 | Astudy on the efficacy and safety of Oselta mivir in the treatment of suspected influenza patients | 2005 | 1 |
| 20 | The impact of the neonatal resuscitation program guidelines (NRPG) on the neonatal mortality in a hospital in Zhuhai, China. | 1997 | 78 |
About Xiaoyu Zhu
Xiaoyu Zhu is a scholar working on Hematology, Oncology and Immunology, having authored 131 papers that have together received 2.2k indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (43 papers), Immune Cell Function and Interaction (22 papers), Advanced Breast Cancer Therapies (20 papers), HER2/EGFR in Cancer Research (19 papers), Acute Myeloid Leukemia Research (17 papers), Cancer Treatment and Pharmacology (15 papers), Cytomegalovirus and herpesvirus research (12 papers) and Polyomavirus and related diseases (10 papers). The work is most often cited by research in Oncology (1.0k citations), Genetics (346 citations) and Hematology (255 citations). Xiaoyu Zhu has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Jianjun Zou, Qian Du, Zimin Sun, Baolin Tang, Zhongsheng Tong, Zefei Jiang, Xichun Hu, Quchang Ouyang, Fei Ma and Huilan Liu. Their work appears in journals such as Cell, Nature Communications and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.